Nice overview Tommy.
4. New revenue stream will be created in Q3 this calendar year through the launch of new vascular repair product.
The trial for this product should finish recruiting in June 2016 with secondary outcome data ....
................The OR data from the procedure including blood loss and how long it took to achieve hemostasis in addition to surgeon feedback on bleeding, handling, and suturing of the material............ should be available soon after however, the primary endpoint .......
...........The 6 month duplex US report will measure peak velocity and flow through the repaired carotid artery, caliber, and occlusion/lesion status as per normal parameters used in post-CEA scans.......... may take until the end of the year for outcome to be known.
But, with the CHD and AV repair experience, clinicians could be happy to use it earlier.
March 16 Quarterly Report - Good and Bad, page-2
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.20 |
Change
-0.800(5.71%) |
Mkt cap ! $279.0M | |||
| Open | High | Low | Value | Volume |
| $14.00 | $14.00 | $13.11 | $947.2K | 71.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.35 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |